DSM and JLL Partners (New York), a middle-market private equity firm, will create a new company, which will be a leading, global contract development and manufacturing organization (CDMO) for the pharmaceutical industry with anticipated sales of about $2 billion in 2014, DSM says. The company will be formed by combining DSM Pharmaceutical Products (Parsippany, NJ), the custom manufacturing and technology business of DSM, with Patheon (Toronto), a portfolio company of JLL. The new company will be 51% owned by JLL and 49% by DSM. The name of the new company will be...
Access is for Chemweek 24/7 PLUS Members ONLY
This information is only available to Chemweek 24/7 PLUS members who have subscribed to Chemweek’s Business Daily. If you are a member, please log in, OR if you have a trial membership, please use your trial membership account information.
Forgot your user ID or password? Click here to have it sent to you.